Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivonescimab for Previously Treated Thymic Carcinoma
NCT06980077Phase 2Recruiting
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- Jul 2025
- Primary completion
- Jun 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ivonescimab in thymic carcinoma (TC), sponsored by UCLA Jonsson Comprehensive Cancer Center. Started Jul 2025; status: recruiting.
02
Drugs
ivonescimab
03
Conditions
thymic carcinoma (TC)
Beyond the preview
Go deeper on NCT06980077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06980077.